查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
头颈癌治疗市场规模、份额和趋势分析报告：按治疗类型（化学疗法、免疫疗法、靶向疗法）、给药途径、分销渠道、地区、细分市场、2022-2030 年预测
市场调查报告书
商品编码
1170875

头颈癌治疗市场规模、份额和趋势分析报告：按治疗类型（化学疗法、免疫疗法、靶向疗法）、给药途径、分销渠道、地区、细分市场、2022-2030 年预测

Head And Neck Cancer Therapeutics Market Size, Share & Trends Analysis Report By Therapy Type (Chemotherapy, Immunotherapy, Targeted Therapy), By Route Of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2022 - 2030
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10个工作天内

价格

头颈癌药物市场增长及趋势

Grand View Research, Inc. 的一份新报告预测，到 2030 年，全球头颈癌药物市场将达到 35 亿美元。从 2022 年到 2030 年，该市场预计将以 12.5% 的复合年增长率增长。头颈癌 (HNC) 诊断和治疗的不断进步预计将推动市场增长，因为它比手术更具成本效益和针对性。各种类型的 HNC 患病率上升和老年人口增加是市场的主要驱动力。

根据癌症研究所的数据，到 2021 年，美国将有大约 54,000 人被诊断出患有不同类型的 HNC，并且将有大约 11,000 人死亡。大量饮酒、长时间暴露在阳光下、爱泼斯坦-巴尔病毒 (EBV) 等致癌病毒感染以及吸烟是全球各种头颈癌发病的主要原因。被认为是病因。

据联合国统计，到 2020 年，全球 60 岁以上的人口将达到约 7.27 亿。此外，预计老年人口将从 2020 年的 9.3% 增加到 2050 年的 16%。衰老会削弱免疫系统，使人们更容易感染各种类型的 HNC，从而导致对治疗该疾病的治疗药物的需求增加。

此外，为开发新型靶向药物和多模式治疗方法而增加的研发活动有望提高头颈癌患者的生存率。例如，Merck/Debiopharm 的 Xevipanant 目前正处于治疗鳞状头颈癌的 III 期临床试验阶段。它还被美国FDA指定为突破性疗法。

预计支持性报销政策也将推动市场增长。一些组织为患者及其护理人员购买药物提供经济援助。例如，2022 年 7 月，Uk columbia cancer将卡培他滨、卡铂、西妥昔单抗、顺铂、多西紫杉醇、多柔比星、氟尿嘧啶和亚叶酸钙列入其有益药物清单。此列表中包含的药物有资格获得批准适应症的报销。

头颈癌治疗市场报告重点

按治疗类型划分，免疫治疗细分市场在 2021 年占据了最大的市场份额，这是由于支持性报销政策的存在以及免疫治疗药物作为头颈癌疾病的有效治疗方法的高效性。

通过给药途径，口服给药部分预计在预测期内增长最快。这是因为这种给药途径在罕见病患者中具有很高的安全性、有效性和耐受性

按分销渠道划分，零售和专业药房部分在 2021 年主导了市场。这种优势可能是由于肿瘤学家对专业药房的偏好。肿瘤学家通常需要专业药房，因此丰富的治疗知识可以支持治疗计划并减轻行政负担

预计亚太地区将成为预测期内增长最快的地区。该地区增长的背后是新产品进入该地区。例如，2020年，NMPA批准Merck & Co., Inc.开发的ERBITUX（西妥昔单抗）在中国用于治疗头颈癌患者。

目录

第一章 调查方法和范围

  • 市场细分
    • 段范围
    • 区域范围
  • 调查方法
  • 信息采购
    • 购买的数据库
    • GVR 内部数据库
    • 次要信息
    • 初步调查
    • 第一次调查的内容
  • 信息或数据分析
    • 数据分析模型
  • 市场製定和验证
  • 型号详情
    • 商品流向分析
      • 方法一：商品流动方法
      • 方法 2：使用自下而上的方法逐个国家/地区进行市场估算
      • 方法 3：使用自上而下的方法逐个国家/地区进行市场估算
  • 全球市场：复合年增长率计算
  • 调查假设
  • 主要 KoL 响应
  • 市场份额计算
  • 二级信息列表
  • 目的
  • 缩略语表

第二章执行摘要

  • 市场概况

第三章头颈癌治疗市场——行业展望

  • 市场系列展望
    • 父市场血统展望
    • 相关/子公司市场展望
  • 绘製渗透率和增长前景
  • 市场动态
    • 市场驱动力分析
      • 头颈癌患病率增加
      • 老年人口不断增长
      • 增加研发和强大的管道产品存在
      • 支持性报销政策和日益增长的疾病意识
    • 市场约束因素分析
      • 缺乏安全性和有效性数据
      • 治疗费用高
  • 头颈癌治疗市场分析工具
    • 行业分析 - 搬运工
    • SWOT 分析，按因素（政治和法律、经济和技术）
      • 政治与法律
      • 经济与社会
      • 技术
  • 赎回和监管场景
    • 北美
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 多边环境协定
  • 重大交易和战略联盟
    • 新产品发布
    • 获得
    • 扩张
    • 合伙
  • 管道分析

第 4 章头颈癌治疗市场分析：治疗类型范围，2018-2030 年（收入，百万美元）

  • 头颈癌治疗市场：治疗类型的变化分析
  • 化学处理
  • 免疫疗法
  • 靶向治疗

5 头颈癌治疗市场分析：剂量范围路线，2018-2030（收入，百万美元）

  • 头颈癌治疗市场：给药途径的变化分析
  • 注射
  • 口服

第 6 章头颈癌治疗市场分析：分销渠道覆盖范围，2018-2030 年（收入，百万美元）

  • 头颈癌治疗药物市场：分销渠道的变化分析
  • 零售和专业药店
  • 医院药房
  • 网上药店

第 7 章头颈癌治疗市场分析，区域范围，2017-2030 年，（收入，百万美元）

  • 2021 年和 2030 年区域市场份额分析
    • 北美
      • 美国
      • 加拿大
    • 欧洲
      • 英国
      • 德国
      • 法国
      • 意大利
      • 西班牙
    • 亚太地区
      • 日本
      • 中国
      • 印度
      • 澳大利亚
      • 韩国
    • 拉丁美洲
      • 巴西
      • 墨西哥
      • 阿根廷
    • 中东和非洲 (MEA)
      • 南非
      • 沙特阿拉伯
      • 南非

8 头颈癌治疗市场：竞争分析

  • 主要市场进入者的最新发展和影响分析
    • 安索夫矩阵
  • 公司分类
    • 创新者
      • 市场差异化因素
  • 供应商情况
    • 主要经销商及渠道合作伙伴名单
    • 主要客户
    • 2020 年主要参与者的市场份额分析
  • 上市公司
    • 公司市场分析
    • 竞争仪錶盘分析
  • 民营企业
    • 主要初创企业名单
  • Regional Network Map
  • 公司简介
    • Eli Lilly and Company
      • 公司简介
      • 财务绩效
      • 产品基准
      • 战略举措
    • Sanofi
      • 公司简介
      • 财务绩效
      • 产品基准
      • 战略举措
    • Merck & Co., Inc.
      • 公司简介
      • 财务绩效
      • 产品基准
      • 战略举措
    • Clingen Group plc.
      • 公司简介
      • 财务绩效
      • 产品基准
      • 战略举措
    • Bristol-Mayers Squibb Company
      • 公司简介
      • Affymetrix
      • 公司简介
      • 财务绩效
      • 产品基准
      • 战略举措
    • Takeda Pharmaceutical Company Limited
      • 公司简介
      • 财务绩效
      • 产品基准
      • 战略举措
    • Teva Pharmaceutical Industries Ltd
      • 公司简介
      • 财务绩效
      • 产品基准
      • 战略举措
    • F. Hoffmann-La Roche Ltd.
      • 公司简介
      • 财务绩效
      • 产品基准
      • 战略举措
Product Code: GVR-2-68038-125-2

Head And Neck Cancer Therapeutics Market Growth & Trends:

The global head and neck cancer therapeutics market size is expected to reach USD 3.5 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 12.5% from 2022 to 2030. Increasing advancements in the diagnosis and treatment of head and neck cancer (HNC) are anticipated to propel market growth, as they are cost-effective and more specific to target over surgeries. The increasing prevalence of different types of HNCs and the growing geriatric population are major drivers of the market.

According to the Cancer Research Institute, in 2021, approximately 54,000 people were diagnosed with different types of HNC and about 11,000 deaths were reported in the U.S. Heavy alcohol consumption, prolonged sun exposure, cancer-causing viral infection such as Epstein-Barr virus (EBV) and tobacco consumption are some of the major factors contribute to rising incidence of various head and neck cancers worldwide.

Furthermore, according to the United Nations, it was estimated that, in 2020, there were around 727 million people aged 60 years and above worldwide. In addition, the geriatric population is expected to increase from 9.3% in 2020 to 16% in 2050. Aging weakens the immune system and makes people susceptible to different types HNCs, consequently, increasing the demand for therapeutic drugs for the treatment of disease.

Moreover, an increase in R&D activities for the development of novel targeted drugs and a multidisciplinary therapeutic approach is expected to lead to an increased survival rate of patients suffering from head and neck cancers. For instance, Merck/Debiopharm's Xevinapant is currently in phase III clinical trials for the treatment of squamous head and neck cancer. It has received breakthrough therapy designation from the U.S. FDA.

Supportive reimbursement policies are also expected to drive market growth. Several organizations provide financial assistance to patients and their caregivers for purchasing medicines. For instance, in July 2022, British Colombia Cancer included Capecitabine, Carboplatin, Cetuximab, Cisplatin, Docetaxel, Doxorubicin, Fluorouracil, and Leucovorin Calcium in their benefit drug list. Drugs included in this list are applicable for reimbursement for approved indications.

Head And Neck Cancer Therapeutics Market Report Highlights:

  • By therapy type, the immunotherapy segment held the largest market share in 2021 due to the presence of supportive reimbursement policies and the higher efficacy of immunotherapy drugs as an effective treatment for head and neck cancer diseases
  • By route of administration, the oral segment is expected to be the fastest-growing segment during the forecast period. This can be attributed to the high safety, efficacy, and tolerability associated with this route of administration among rare disease patients
  • By distribution channel, the retail and specialty pharmacy segment dominated the market in 2021. This dominance can be attributed to the preference of oncologists for specialty pharmacies. Oncologists often need specialty pharmacies so that with extensive therapeutic knowledge, they can support treatment plans and relieve them from the administrative burden
  • Asia Pacific is expected to be the fastest-growing region during the forecast period. The growth of the region can be attributed to the entry of new products into the region. For instance, in 2020, NMPA approved ERBITUX (Cetuximab) developed by Merck and Co., Inc., to treat patients with head and neck cancer in China

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market Segmentation
    • 1.1.1 Segment scope
    • 1.1.2 Regional scope
    • 1.1.3 Estimates and Forecast Timeline
  • 1.2 Research Methodology
  • 1.3 Information Procurement
    • 1.3.1 Purchased Database
    • 1.3.2 GVR's Internal Database
    • 1.3.3 Secondary Sources
    • 1.3.4 Primary Research
    • 1.3.5 Details of Primary Research
  • 1.4 Information or Data Analysis
    • 1.4.1 Data Analysis Models
  • 1.5 Market Formulation & Validation
  • 1.6 Model Details
    • 1.6.1 Commodity Flow Analysis
      • 1.6.1.1 Approach 1: Commodity flow approach
      • 1.6.1.2 Approach 2: Country wise market estimation using bottom up approach
      • 1.6.1.3 Approach 3: Country wise market estimation using top down approach
  • 1.7 Global Market: CAGR Calculation
  • 1.8 Research Assumptions
  • 1.9 Key KoL Responses
  • 1.10 Market Share Calculations
  • 1.11 List of Secondary Sources
  • 1.12 Objectives
    • 1.12.1 Objective 1:
    • 1.12.2 Objective 2:
  • 1.13 List of Abbreviations

Chapter 2 Executive Summary

  • 2.1 Market Summary

Chapter 3 Head and Neck Cancer Therapeutics Market - Industry Outlook

  • 3.1 Market Lineage Outlook
    • 3.1.1 Parent Market Lineage Outlook
    • 3.1.2 Related/Ancillary Market Outlook
  • 3.2 Penetration & Growth Prospect Mapping
  • 3.3 Market Dynamics
    • 3.3.1 Market Drivers Analysis
      • 3.3.1.1 Increasing prevalence of head and neck cancers
      • 3.3.1.2 Rising geriatric population
      • 3.3.1.3 Increasing R&D and strong presence of pipeline product
      • 3.3.1.4 Supportive reimbursment policies and rising awareness about disease
    • 3.3.2 Market Restraint Analysis
      • 3.3.2.1 Paucity of data related to safety and efficacy
      • 3.3.2.2 High cost of treatments
  • 3.4 Head and Neck Cancer Therapeutics Market Analysis Tools
    • 3.4.2 Industry Analysis - Porter's
    • 3.4.3 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
      • 3.4.3.1 Political and Legal
      • 3.4.3.2 Economic & Social
      • 3.4.3.3 Technological
  • 3.5 Reimbursement & Regulatory Scenario
    • 3.5.1 North America
    • 3.5.1 Europe
    • 3.5.2 Asia Pacific
    • 3.5.3 Latin America
    • 3.5.4 MEA
  • 3.6 Major Deals & Strategic Alliances
    • 3.6.1 New Product Launch
    • 3.6.2 Acquisition
    • 3.6.3 Expansion
    • 3.6.4 Partnerships
  • 3.7 Pipeline analysis

Chapter 4 Head and Neck Cancer Therapeutics Market Analysis: Therapy Type Scope, 2018 - 2030 (Revenue, USD Million)

  • 4.1 Head and Neck Cancer Therapeutics Market: Therapy Type Movement Analysis
  • 4.2 Chemotherapy
    • 4.2.1 Chemotherapy market estimates and forecast, 2018 - 2030 (USD million)
  • 4.3 Immunotherapy
    • 4.3.1 Immunotherapy market estimates and forecast, 2018 - 2030 (USD million)
  • 4.4 Targeted Therapy
    • 4.4.1 Targeted therapy market estimates and forecast, 2018 - 2030 (USD million)

Chapter 5 Head and Neck Cancer Therapeutics Market Analysis: Route of Administration Scope, 2018 - 2030 (Revenue, USD Million)

  • 5.1 Head and Neck Cancer Therapeutics Market: Route of Administration Movement Analysis
  • 5.2 Injectables
    • 5.2.1 Injectables market estimates and forecast, 2018 - 2030 (USD million)
  • 5.3 Oral
    • 5.3.1 Oral market estimates and forecast, 2018 - 2030 (USD million)

Chapter 6 Head and Neck Cancer Therapeutics Market Analysis: Distribution Channel Scope, 2018 - 2030 (Revenue, USD Million)

  • 6.1 Head and Neck Cancer Therapeutics Market: Distribution Channel Movement Analysis
  • 6.2 Retail & Specialty Pharmacies
    • 6.2.1 Retail & specialty pharmacies market estimates and forecast, 2018 - 2030 (USD million)
  • 6.3 Hospital Pharmacies
    • 6.3.1 Hospital pharmacies market estimates and forecast, 2018 - 2030 (USD million)
  • 6.4 Online Pharmacies
    • 6.4.1 Online pharmacies market estimates and forecast, 2018 - 2030 (USD million)

Chapter 7 Head and Neck Cancer Therapeutics Market Analysis, Regional Scope, 2017-2030, (Revenue, USD Million)

  • 7.1 Market Share Analysis by Regional, 2021 & 2030
    • 7.1.1 North America
      • 7.1.1.1 North America market estimates and forecast, 2018 - 2030 (USD Million)
      • 7.1.1.2 U.S.
      • 7.1.1.2.1 U.S. market estimates and forecast, 2018 - 2030 (USD Million)
      • 7.1.1.3 Canada
      • 7.1.1.3.1 Canada market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.1.2 Europe
      • 7.1.2.1 Europe market estimates and forecast, 2018 - 2030 (USD Million)
      • 7.1.2.2 U.K.
      • 7.1.2.2.1 U.K. market estimates and forecast, 2018 - 2030 (USD Million)
      • 7.1.2.3 Germany
      • 7.1.2.3.1 Germany market estimates and forecast, 2018 - 2030 (USD Million)
      • 7.1.2.4 France
      • 7.1.2.4.1 France market estimates and forecast, 2018 - 2030 (USD Million)
      • 7.1.2.5 Italy
      • 7.1.2.5.1 Italy market estimates and forecast, 2018 - 2030 (USD Million)
      • 7.1.2.6 Spain
      • 7.1.2.6.1 Spain market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.1.3 Asia Pacific
      • 7.1.3.1 Asia Pacific market estimates and forecast, 2018 - 2030 (USD Million)
      • 7.1.3.2 Japan
      • 7.1.3.2.1 Japan market estimates and forecast, 2018 - 2030 (USD Million)
      • 7.1.3.3 China
      • 7.1.3.3.1 China market estimates and forecast, 2018 - 2030 (USD Million)
      • 7.1.3.4 India
      • 7.1.3.4.1 India market estimates and forecast, 2018 - 2030 (USD Million)
      • 7.1.3.5 Australia
      • 7.1.3.5.1 Australia market estimates and forecast, 2018 - 2030 (USD Million)
      • 7.1.3.6 South Korea
      • 7.1.3.6.1 South Korea market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.1.4 Latin America
      • 7.1.4.1 Latin America market estimates and forecast, 2018 - 2030 (USD Million)
      • 7.1.4.2 Brazil
      • 7.1.4.2.1 Brazil market estimates and forecast, 2018 - 2030 (USD Million)
      • 7.1.3.3 Mexico
      • 7.1.3.3.1 Mexico market estimates and forecast, 2018 - 2030 (USD Million)
      • 7.1.3.4 Argentina
      • 7.1.3.4.1 Argentina market estimates and forecast, 2018 - 2030 (USD Million)
    • 7.1.5 Middle East and Africa (MEA)
      • 7.1.8.1 Middle East & Africa market estimates and forecast, 2018 - 2030 (USD Million)
      • 7.1.8.2 South Africa
      • 7.1.8.2.1 South Africa market estimates and forecast, 2018 - 2030 (USD Million)
      • 7.1.3.3 Saudi Arabia
      • 7.1.3.3.1 Saudi Arabia market estimates and forecast, 2018 - 2030 (USD Million)
      • 7.1.3.4 South Africa
      • 7.1.3.4.1 South Africa market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 8 Head and Neck Cancer Therapeutics Market: Competitive Analysis

  • 8.1 Recent Developments and Impact Analysis, by Key Market Participants
    • 8.1.1 Ansoff matrix`
  • 8.2 Company Categorization
    • 8.2.1 Innovators
      • 8.2.2.1 Market Differentiators
  • 8.3 Vendor Landscape
    • 8.3.1 List of Key Distributors And Channel Partners
    • 8.3.2 Key Customers
    • 8.3.3 Key Company Market Share Analysis, 2020
  • 8.4 Public Companies
    • 8.4.1 Comapany Market Position analysis
    • 8.4.2 Competitive dashboard analysis
  • 8.5 Private Companies
    • 8.5.1 List of Key Emerging Companies
  • 8.6 Regional Network Map
  • 8.8 Company Profiles
    • 8.8.1 Eli Lilly and Company
      • 8.8.1.1 Company overview
      • 8.8.1.2 Financial performance
      • 8.8.1.3 Product benchmarking
      • 8.8.1.4 Strategic initiatives
    • 8.8.2 Sanofi
      • 8.8.2.1 Company overview
      • 8.8.2.2 Financial performance
      • 8.8.2.3 Product benchmarking
      • 8.8.2.4 Strategic initiatives
    • 8.8.3 Merck & Co., Inc.
      • 8.8.3.1 Company overview
      • 8.8.3.2 Financial performance
      • 8.8.3.3 Product benchmarking
      • 8.8.3.4 Strategic initiatives
    • 8.8.4 Clingen Group plc.
      • 8.8.4.1 Company overview
      • 8.8.4.2 Financial performance
      • 8.8.4.3 Product benchmarking
      • 8.8.4.4 Strategic initiatives
    • 8.8.5 Bristol-Mayers Squibb Company
      • 8.8.5.1 Company overview
      • 8.8.5.2 Affymetrix
      • 8.8.5.3 Company overview
      • 8.8.5.4 Financial performance
      • 8.8.5.5 Product benchmarking
      • 8.8.5.6 Strategic initiatives
    • 8.8.6 Takeda Pharmaceutical Company Limited
      • 8.8.6.1 Company overview
      • 8.8.6.2 Financial performance
      • 8.8.6.3 Product benchmarking
      • 8.8.6.4 Strategic initiatives
    • 8.8.7 Teva Pharmaceutical Industries Ltd
      • 8.8.7.1 Company overview
      • 8.8.7.2 Financial performance
      • 8.8.7.3 Product benchmarking
      • 8.8.7.4 Strategic initiatives
    • 8.8.8 F. Hoffmann-La Roche Ltd.
      • 8.8.8.1 Company overview
      • 8.8.8.2 Financial performance
      • 8.8.8.3 Product benchmarking
      • 8.8.8.4 Strategic initiatives

List of Tables

  • TABLE 1 List of Secondary Sources
  • TABLE 2 List of Abbreviations
  • TABLE 3 Global Head and Neck Cancer Therapeutics Market, By Region, 2018 - 2030 (USD Million)
  • TABLE 4 Global Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
  • TABLE 5 Global Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • TABLE 6 Global Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 7 North America Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
  • TABLE 8 North America Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • TABLE 9 North America Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 10 U.S. Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
  • TABLE 11 U.S. Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • TABLE 12 U.S. Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 13 Canada Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
  • TABLE 14 Canada Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • TABLE 15 Canada Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 16 Europe Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
  • TABLE 17 Europe Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • TABLE 18 Europe Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 19 Germany Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
  • TABLE 20 Germany Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • TABLE 21 Germany Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 22 U.K. Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
  • TABLE 23 U.K. Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • TABLE 24 U.K. Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 25 France Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
  • TABLE 26 France Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • TABLE 27 France Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 28 Italy Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
  • TABLE 29 Italy Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • TABLE 30 Italy Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 31 Spain Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
  • TABLE 32 Spain Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • TABLE 33 Spain Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 34 Asia Pacific Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
  • TABLE 35 Asia Pacific Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • TABLE 36 Asia Pacific Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 37 Japan Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
  • TABLE 38 Japan Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • TABLE 39 Japan Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 40 China Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
  • TABLE 41 China Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • TABLE 42 China Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 43 India Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
  • TABLE 44 India Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • TABLE 45 India Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 46 South Korea Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
  • TABLE 47 South Korea Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • TABLE 48 South Korea Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 49 Australia Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
  • TABLE 50 Australia Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • TABLE 51 Austalia Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 52 Latin America Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
  • TABLE 53 Latin America Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • TABLE 54 Latin America Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 55 Brazil Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
  • TABLE 56 Brazil Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • TABLE 57 Brazil Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 58 Mexico Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
  • TABLE 59 Mexico Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • TABLE 60 Mexico Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 61 Argentina Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
  • TABLE 62 Argentina Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • TABLE 63 Argentina Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 64 Middle East & Africa Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
  • TABLE 65 Middle East & Africa Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • TABLE 66 Middle East & Africa Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 67 Saudi Arabia Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
  • TABLE 68 Saudi Arabia Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • TABLE 69 Saudi Arabia Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 70 South Africa Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
  • TABLE 71 South Africa Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • TABLE 72 South Africa Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • TABLE 73 UAE Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
  • TABLE 74 UAE Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • TABLE 75 UAE Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)

List of Figures

  • FIG. 1 Head and neck cancer therapeutics market segmentation
  • FIG. 2 Market research process
  • FIG. 3 Data triangulation techniques
  • FIG. 4 Primary research pattern
  • FIG. 5 Market research approaches
  • FIG. 6 Value-chain-based sizing & forecasting
  • FIG. 7 QFD modelling for market share assessment
  • FIG. 8 Market formulation & validation
  • FIG. 9 Head and neck cancer therapeutics market snapshot
  • FIG. 10 Parent market outlook
  • FIG. 11 Related/ancillary market outlook, revenue, 2021, (USD Million)
  • FIG. 12 Penetration and growth prospect mapping
  • FIG. 13 Head and neck cancer therapeutics market driver impact
  • FIG. 14 Head and neck cancer therapeutics market restraint impact
  • FIG. 15 SWOT analysis, by factor (political & legal, economic, and technological)
  • FIG. 16 Industry Analysis - Porter's
  • FIG. 17 Strategy mapping
  • FIG. 18 Head and neck cancer therapeutics market: Therapy type outlook and key takeaways
  • FIG. 19 Head and neck cancer therapeutics market: Therapy type movement analysis & market share 2021 & 2030
  • FIG. 20 Chemotherapy market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 21 Immunotherapy market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 22 Targeted therapy market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 23 Head and neck cancer therapeutics market: Route of Administration outlook and key takeaways
  • FIG. 24 Head and neck cancer therapeutics market: Route of administration movement analysis & market share 2021 & 2030
  • FIG. 25 Injectable market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 26 Oral market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 27 Head and neck cancer therapeutics market: Distribution Channel outlook and key takeaways
  • FIG. 28 Head and neck cancer therapeutics market: Distribution Channel movement analysis & market share 2021 & 2030
  • FIG. 29 Retail & specialty pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 30 Hospital pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 31 Online pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 32 Head and neck cancer therapeutics: Regional outlook and key takeaways
  • FIG. 33 Regional outlook, 2021 & 2030
  • FIG. 34 North America
  • FIG. 35 North America market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 36 U.S.
  • FIG. 37 U.S. market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 38 Canada
  • FIG. 39 Canada market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 40 Europe
  • FIG. 41 Europe market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 42 U.K.
  • FIG. 43 U.K. market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 44 Germany
  • FIG. 45 Germany market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 46 France
  • FIG. 47 France market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 48 Italy
  • FIG. 49 Italy market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 50 Spain
  • FIG. 51 Spain market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 52 Asia Pacific
  • FIG. 53 Asia Pacific market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 54 Japan
  • FIG. 55 Japan market estimates and forecast, 2018 - 2030(USD Million)
  • FIG. 56 China
  • FIG. 57 China market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 58 India
  • FIG. 59 India market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 60 South Korea
  • FIG. 61 South Korea market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 62 Australia
  • FIG. 63 Australia market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 64 Latin America
  • FIG. 65 Latin America market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 66 Brazil
  • FIG. 67 Brazil market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 68 Mexico
  • FIG. 69 Mexico market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 70 Argentina
  • FIG. 71 Argentina market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 72 Middle East & Africa
  • FIG. 73 MEA market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 74 South Africa
  • FIG. 75 South Africa market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 76 Saudi Arabia
  • FIG. 77 Saudi Arabia market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 78 UAE
  • FIG. 79 UAE market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 80 Market differentiators
  • FIG. 81 Key company market share analysis, 2021
  • FIG. 82 Company market position analysis
  • FIG. 83 Competitive dashboard analysis
  • FIG. 84 Regional network map